Germany's IQWiG positive on Olysio's added benefit
This article was originally published in Scrip
Executive Summary
Johnson & Johnson has secured a fairly positive outcome from Germany's health technology appraisal body, IQWiG, which has judged that hepatitis C (HCV) drug Olysio (simeprevir) provides additional benefit in some patients.